Forge Biologics Announces Closing of $120 Million Series B Financing
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund will join the Company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005365/en/
“We are very pleased to be working with RA Capital and a strong syndicate of top-tier life sciences investors who share our vision as we now advance our growth as a global gene therapy manufacturing and development company,” said Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics. “We have built Forge into a focused gene therapy development engine with a firm commitment to helping our clients provide potentially life-saving gene therapies to patients. We believe that focusing entirely on gene therapy will allow us to best serve our clients and patients by efficiently delivering high quality product.”
Forge will use the proceeds of this Series B financing to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel AAV gene therapy programs. Forge brings a patients-first approach to accelerate the development of transformative medicines for those who need them most and is addressing the growing demand for gene therapy manufacturing capacity. Through its currently-operational 175,000 square foot cGMP facility in Columbus, Ohio, dedicated to AAV viral vector manufacturing, Forge offers end-to-end manufacturing services, including research and toxicology grade AAV production, to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
“The success of complex biologics like AAV is exhausting existing manufacturing capacity around the industry. This financing will help to address this industry-wide capacity shortage by properly capitalizing an emerging gene therapy-focused CDMO capable of producing high quality cGMP product for its clients,” said Matthew Hammond, Ph.D., principal at RA Capital Management. “We are confident that Forge’s experienced team will become the trusted partner of innovative therapeutics companies, working collaboratively with clients to successfully deliver AAV manufacturing solutions.”
Through its subsidiaries, Forge is also working to advance a proprietary pipeline of novel gene therapies, including its lead program FBX-101 for the treatment of patients with Krabbe disease, a first-in-human gene therapy utilizing an adeno-associated virus (AAV) to deliver a functioning copy of the GALC gene intravenously to cells in the central nervous system (CNS) and peripheral organs.
Chardan Capital Markets acted as exclusive placement agent for the offering, with Ice Miller acting as legal advisor.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 square foot facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
For more information, please visit https://www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Director of Communications and Community Development
Forge Biologics Inc.
Vice President and Head of Business Development
Forge Biologics Inc.
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Forge Biologics Inc.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
iProov Achieves Record-breaking Growth as Demand for Genuine Presence Assurance ™ Soars29.7.2021 06:01:00 CEST | Press release
iProov, world leader in secure biometric authentication technology, today announced record-breaking growth in the first half of 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006091/en/ iProov's Genuine Presence Assurance™ technology verifies that an online user is the right person, a real person, authenticating right now. (Photo: Business Wire) From January to June 2021, iProov saw a 15x increase in the number of people verified using its technology versus the same time period last year. Its flagship Genuine Presence Assurance technology solidified its global market leadership, with verifications growing at a consistent rate of 25% per month worldwide. This has been driven by demand from organizations needing to verify the identity of online users to prevent fraud. iProov’s patented technology assures the genuine presence of an online user to ensure they are the right person, a real person, and authenticating ri
Wemade Co., Ltd. Announces Pre-Registration for MIR 4, an Open World K-Fantasy MMORPG29.7.2021 05:00:00 CEST | Press release
“From my battle to our war.” MIR 4, the unique open world K-Fantasy MMORPG, opens for global pre-registration on Thursday, 29 July. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006129/en/ Wemade 's MIR 4, the unique open world K-Fantasy MMORPG, opens for global pre-registration on Thursday, 29 July. Pre-registration will be available on MIR 4’s official website, the Google Play Store and the Apple App Store. Pre-registered users will enjoy various in-game items on launch. The game beautifully portrays the mystical and elegant life of the Orient, offering a truly singular experience for MMORPG players across the world. The global version is upgraded from the Korean in that it has adopted blockchain technology. The digital assets in MIR 4 can be made NFT or FT in order to buy, sell or trade for profit. The global release will be available in more than 170 countries on both mobile and PC. (Graphic: Business Wire) The ga
Riskified Ltd. Announces Pricing of Initial Public Offering29.7.2021 01:57:00 CEST | Press release
Riskified Ltd. (“Riskified”), a fraud management platform enabling frictionless eCommerce, today announced the pricing of its initial public offering of 17,500,000 Class A ordinary shares at a public offering price of $21.00 per Class A ordinary share. The offering consists of 17,300,000 Class A ordinary shares offered by Riskified and 200,000 Class A ordinary shares to be sold by one of Riskified’s existing shareholders. Riskified will not receive any proceeds from the sale of the shares by the selling shareholder. The underwriters will have a 30-day option to purchase up to an additional 2,625,000 Class A ordinary shares from Riskified at the initial public offering price, less underwriting discounts and commissions. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on July 29, 2021 under the ticker symbol “RSKD”. The closing of the offering is expected to occur on August 2, 2021 subject to the satisfaction of customary closing conditions. Goldm
IFF Appoints Nicolas Mirzayantz President of IFF’s Nourish Division28.7.2021 22:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, current President, Scent, has been appointed President of IFF’s Nourish division, effective September 1, 2021. Mr. Mirzayantz will succeed Kathy Fortmann, current President, Nourish, who has decided to pursue other opportunities outside of IFF. IFF veteran and current President, Global Consumer Fragrances, Christophe de Villeplee, will assume transition into the role of President, Scent. “We could not be more pleased to have Nicolas lead our Nourish division,” said IFF Chairman and CEO, Andreas Fibig. “Nicolas is joining a Nourish division with a tremendous opportunity to build on significant sales momentum and strong customer interest in IFF’s differentiated portfolio and capabilities. He has been an invaluable member of our leadership team, with an unparalleled ability to create a culture of innovation and deliver creative and winning solutions to our customers while consistently strengthening the business through growth and ma
Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System28.7.2021 18:26:00 CEST | Press release
Stilla Technologies, the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industry’s first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today. This represents a broad portfolio expansion of the Company’s original three-color naica® system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software. The commercial launch of the six-color naica® system is scheduled for Fall 2021. “There is undeniable value in detecting and quantifying multiple mutations, viruses and biomarkers from a single sample. The cost versus depth tradeoffs of NGS make it impractical for the routine testing of many samples per day, while multiplex qPCR lacks the precise quantitation a
Q4 Helps Public Companies and Investment Firms Keep Their Teams Aligned and Informed28.7.2021 15:00:00 CEST | Press release
Q4 Inc. announced today it is applying its unique expertise in delivering mission-critical virtual events to help public companies, buy-side and sell-side firms build transparency, trust and excitement across a widely dispersed workforce. With the seismic shift in working models giving employees increasing flexibility to work both in remote or hybrid setups, maintaining a strong internal communications platform to globally distributed teams is vital for companies across all industries. Simultaneously, the commitment to providing a sustainable work environment and strong corporate culture continues to intensify as companies seek to implement successful ESG policies and programs. Q4’s new Corporate Town Hall subscriptions combine technology and a premium end-to-end service model to help its capital markets clients communicate strategy and best practices, provide quarterly business reviews, host sales kick-offs, and ultimately foster the inclusive culture they have worked so hard to devel
ZS Elects Pratap Khedkar to CEO28.7.2021 15:00:00 CEST | Press release
Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/ Pratap Khedkar, CEO, ZS (Photo: Business Wire) Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about. Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom